Laura Hutchins named interim director of UAMS Rockefeller Cancer Institute

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Laura Hutchins, a hematologist-oncologist at the University of Arkansas for Medical Sciences who specializes in breast cancer, melanoma and brain cancer, has been appointed interim director for the UAMS Winthrop P. Rockefeller Cancer Institute, effective immediately.

She succeeds Peter Emanuel, who recently resigned after leading the institute since 2007. A committee will be formed to conduct a national search for a permanent director.

Hutchins is a professor in the College of Medicine Division of Hematology/Oncology where she was division director from 1998 until September 2013. She also has served as director clinical research at the Cancer Institute since 1998 and has held the Virginia Clinton Kelley Endowed Chair for Clinical Breast Cancer Research since 2007.

She has been a co-investigator on numerous NIH grants including those focused on detection of circulating melanoma cells, and using nanotubes to detect and purge circulating cancer cells.

Her research includes collaborating with Thomas Kieber-Emmons, a fellow scientist to study a UAMS-designed vaccine to prevent the recurrence of breast cancer. That vaccine, now in a phase II clinical trial, is being used in women newly diagnosed with breast cancer to determine if the combination of the vaccine and standard chemotherapy improve the benefit of preoperative therapy.

Hutchins was appointed by the governor to the Arkansas Breast Cancer Research Program Oversight Committee from 2001-2004. From 2004-2012, she was appointed to serve on the state Breast Cancer Control Advisory Board, serving as chairman from 2007-2008.

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login